cis-cisoid-cis-perhydroanthracene | 19128-78-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: cis-cisoid-cis-perhydroanthracene
• 英文别名: cis-syn-cis-Perhydroanthracen；(4aS,8aS,9aR,10aR)-1,2,3,4,4a,5,6,7,8,8a,9,9a,10,10a-tetradecahydroanthracene
• CAS: 19128-78-0
• 化学式: C₁₄H₂₄
• 分子量: 192.345
• InChiKey: GVJFFQYXVOJXFI-LVEBTZEWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  cis-cisoid-cis-perhydroanthracene 在 三氯化铝 、 正己烷 作用下， 生成 (4aR,8aS,9aR,10aS)-tetradecahydroanthracene
  参考文献：
  名称：

  76.氢蒽和对菲。第二部分

  摘要：

  DOI：

  10.1039/jr9440000286
• 作为产物：
  描述：

  9,10-二氢蒽 在 溶剂黄146 、 铂 作用下， 生成 cis-cisoid-cis-perhydroanthracene
  参考文献：
  名称：

  76.氢蒽和对菲。第二部分

  摘要：

  DOI：

  10.1039/jr9440000286

文献信息

• Deep hydrogenation of coal tar over a Ni/ZSM-5 catalyst
  作者：Shi-Chao Qi、Lu Zhang、Xian-Yong Wei、Jun-ichiro Hayashi、Zhi-Min Zong、Lu-Lu Guo

  DOI：10.1039/c3ra47701k

  日期：——

  via the hydrogenation of 9,10-diphenylanthracene. Through hydrotreatment over the Ni/ZSM-5 catalyst, both high-temperature coal tar rich in condensed arenes and low-temperature coal tar mixing arenes with alkanes were greatly upgraded. The majority of arenes in the coal tars were deeply and even completely hydrogenated, which may open up a route for further processing and application of coal tar as

  我们已经开发了Ni / ZSM-5催化剂，并利用它在相对温和的条件下将包括萘，蒽和菲在内的一系列缩合芳烃完全加氢。十氢化萘，全氢蒽和全氢菲的收率分别达到100％，98.8％和25.8％。通过分析过氢芳烃的异构体分布，我们提出了双原子氢转移的机理，该机理进一步通过9,10-二苯基蒽的氢化。通过在Ni / ZSM-5催化剂上进行加氢处理，富含冷凝芳烃的高温煤焦油和带有烷烃的低温煤焦油混合芳烃都得到了大幅升级。煤焦油中的大多数芳烃都被深度甚至完全氢化，这可能为进一步处理和应用煤焦油作为清洁燃料开辟一条道路。
• Glucose and Insulin Responses to a New Zero-Energy Fiber Source
  作者：Judith Hallfrisch、Daniel J. Scholfield、Kay M. Behall

  DOI：10.1080/07315724.2002.10719243

  日期：2002.10

  Objective: Consumption of a number of soluble fiber sources reduces glucose and insulin responses in humans. These fibers provide some available energy. Z-trim, a completely insoluble, noncaloric fiber/fat replacer produced from grain, was developed by ARS scientist George Inglett but until this report had not been tested in humans. The objective was to test the effects of consumption of various doses of this new fiber on glucose and insulin responses in humans.Design: Men and women (12 each) matched for age and body mass index (41 years, BMI 27) were given glucose or glucose with three levels of fiber in a Latin-square design. Blood samples were obtained before and 30, 60, 120 and 180 minutes after solutions containing glucose alone (I g/kg body weight) and glucose plus 0.08, 0.17 and 0.33 g/kg body weight of Z-trim were consumed. Plasma glucose, insulin and glucagon were determined by enzyme or radioimmunoassays. A repeated-measures analysis of variance was conducted.Results: Glucose responses were lower for women than for men (p = 0.02) regardless of the test solution. At 30 minutes, glucose levels of men were 0.7-1.1 mmol/L lower after the two higher levels of fiber than after glucose alone. Insulin peak responses were delayed by high amounts of Z-trim. Fasting and response levels of glucagon were higher (p < 0.002) in women than in men. The decline in glucagon usually seen after a glucose load was moderated by the addition of fiber.Conclusion: Although high levels of this new fiber may beneficially affect glucose metabolism of middle-aged people, it is less effective than soluble fiber.
• Potential Steroid Substitutes. I. Introductory Remarks. The Synthesis of Some Dioxoperhydroanthracenes
  作者：Robert L. Clarke、William S. Johnson

  DOI：10.1021/ja01530a045

  日期：1959.11
• A MIODARONE AND R URAL E MERGENCY M EDICAL S ERVICES C ARDIAC A RREST P ATIENTS : A C OST A NALYSIS
  作者：Teresa E. Pazdral、John H. Burton、Tania D. Strout、Jay R. Bradshaw

  DOI：10.1080/10903120290938319

  日期：2002.1

  Objective: Recent American Heart Association guidelines suggest amiodarone as an antiarrhythmic in refractory ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT). The authors sought to assess the impact of amiodarone use on outcomes and cost associated with this practice in a rural emergency medical services (EMS) state. Methods: Statewide EMS records were reviewed for the calendar year 1999. Data reviewed included prehospital diagnosis, medications given by prehospital providers to patients with cardiac arrest, and procedures performed, including cardiopulmonary resuscitation (CPR) and defibrillation. Cost-benefit analysis assumed the cost of amiodarone treatment to be $137.65 per patient encounter. Absolute risk reduction (ARR) and number needed to treat (NNT) analysis utilized resuscitation rates published in the ARREST and ALIVE trials. Results: During the study period, EMS providers diagnosed 2,189 patients as having cardiac arrest. Five hundred thirty-five (24.4%) cardiac arrest patients were defibrillated. One hundred sixty patients (7.3%), including 15 who did not receive defibrillation, were given lidocaine during resuscitation efforts. The annual cost increase from current practice for a statewide amiodarone VF/VT protocol was $21,822.40 (10,572.87%). The initial cost to stock EMS vehicles for this protocol would be $50,115.52. The cost-benefit analysis yielded a potential for one additional patient survival to hospital discharge in Maine per 3.125 years of system-wide practice at a cost of $68,840.00. Conclusion: Based on current data, instituting amiodarone treatment for refractory VF and pulseless VT in a rural EMS setting requires the investment of substantial resources, relative to current treatment strategies, for any potential survival benefit.
• THE CATALYTIC HYDROGENATION OF AROMATIC HYDROCARBONS UNDER HIGH PRESSURE AND HIGH TEMPERATURE
  作者：Ituo Kagehira

  DOI：10.1246/bcsj.6.241

  日期：1931.9

表征谱图